Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREFRIN-A vs VASOCON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Vasoconstrictor; alpha-1 adrenergic receptor agonist causing smooth muscle contraction in blood vessels, reducing nasal congestion and ocular redness.
Temporary relief of nasal congestion,Fever reduction,Mild to moderate pain relief
Relief of nasal congestion due to colds, allergies, sinusitis,Ocular decongestant for redness relief
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
Adults: 2 drops of 0.25% solution in each eye every 4 hours as needed.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Terminal elimination half-life: 2-3 hours; clinically, repeated doses may be needed for sustained effect in conditions like hypotension.
Phenylephrine undergoes extensive first-pass metabolism by monoamine oxidase (MAO) in the liver and gut; acetaminophen is primarily metabolized by glucuronidation and sulfation, with minor CYP2E1 oxidation to a hepatotoxic metabolite NAPQI.
Primarily hepatic via monoamine oxidase (MAO) metabolism.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Primarily renal (60-80% as unchanged drug and metabolites), with minor biliary/fecal elimination (10-20%).
Phenylephrine: 50-60% bound to albumin and alpha-1-acid glycoprotein; Antazoline: ~20% bound to albumin.
Approximately 75-80%, primarily to albumin.
Phenylephrine: Vd ~0.5 L/kg (distributes primarily into extracellular fluid); Antazoline: Vd ~2 L/kg (extensive tissue distribution).
0.3-0.5 L/kg; reflects distribution within extracellular fluid and rapid equilibration with tissues.
Ocular: <1% systemic bioavailability after topical administration; intranasal: 10-20% systemic bioavailability; oral: 2-5% due to first-pass metabolism.
Intramuscular: 100%; Subcutaneous: 100%; Oral: <5% due to extensive first-pass metabolism.
No dosage adjustment required for renal impairment.
No dose adjustment required for renal impairment.
No dosage adjustment required for hepatic impairment.
No dose adjustment required for hepatic impairment.
Children ≥6 years: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily. Children <6 years: not recommended.
Children: 1 drop of 0.125% solution in each eye every 4 hours as needed.
Use with caution due to increased risk of systemic absorption and adverse effects; consider lowest effective dose and frequency.
Use caution due to increased risk of adverse effects; consider lower concentration (0.125%) if needed.
None.
None
Avoid use in patients with hypertension, hyperthyroidism, diabetes, or cardiovascular disease. Risk of hepatotoxicity with acetaminophen overdose. Do not exceed recommended dose. Avoid concurrent use with MAO inhibitors.
Use with caution in hypertension, hyperthyroidism, diabetes, cardiovascular disease, and prostatic hypertrophy. Avoid prolonged use (>3 days nasal, >72 hours ocular) due to rebound congestion. Not recommended in children under 6 years for nasal use.
Hypersensitivity to phenylephrine, acetaminophen, or any excipients. Severe hypertension or coronary artery disease. Concomitant use or within 14 days of MAO inhibitors.
Hypersensitivity to any component, narrow-angle glaucoma, severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, and during pregnancy (first trimester).
Avoid alcohol and products containing caffeine or other stimulants as they may increase the risk of cardiovascular adverse effects. No specific food restrictions beyond maintaining hydration.
No significant food interactions. Avoid excessive caffeine or alcohol as they may exacerbate ocular dryness.
Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction and reduced placental perfusion; risk of fetal hypoxia in third trimester. Pyrilamine: Class B in pregnancy; animal studies show no fetal harm. Avoid in first trimester due to theoretical risk of vasoconstriction. Use only if benefit outweighs risk.
VASOCON (tetrahydrozoline) ophthalmic. Teratogenic risk: Category C. First trimester: No adequate human studies; animal studies not available. Second/third trimester: Potential maternal hypertension or bradycardia may reduce uteroplacental perfusion. Avoid chronic use.
Phenylephrine: minimal excretion in breast milk; M/P ratio unknown. Pyrilamine: not known if excreted. Antihistamines may cause drowsiness or irritability in infant. Avoid if possible due to lack of safety data. Consider alternative with more data.
No human data on excretion into breast milk; M/P ratio unknown. Systemic absorption minimal after ophthalmic dose. Consider benefit versus theoretical risk of infant vasoconstriction.
No specific dose adjustment recommendations due to lack of pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Consider alternative agents if possible.
No standard dose adjustment recommended for ophthalmic use. Avoid systemic use due to potential vasoconstriction and hypertension. Use lowest effective dose for shortest duration.
Prefrin-A combines phenylephrine (alpha-1 agonist vasoconstrictor) with pyrilamine (first-generation antihistamine). Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, diabetes, or narrow-angle glaucoma. Avoid in patients taking MAO inhibitors or within 14 days of discontinuation. Rebound congestion can occur with prolonged use (>3 days). Monitor for CNS depression or paradoxical excitation in children.
VASOCON (naphazoline/phenylephrine) is an ophthalmic decongestant. Avoid in patients with narrow-angle glaucoma due to risk of angle closure. Rebound hyperemia occurs with prolonged use >72 hours. Systemic absorption may cause hypertension, especially in patients on MAOIs or with cardiovascular disease.
Use exactly as directed; do not use for more than 3 days to avoid rebound congestion.,Avoid driving or operating machinery if drowsiness occurs, especially when combined with alcohol or other CNS depressants.,Do not use if you have high blood pressure, heart disease, thyroid problems, diabetes, or glaucoma unless directed by a doctor.,Discontinue use and consult a doctor if symptoms persist or worsen, or if you experience severe dizziness, headache, or irregular heartbeat.,Store at room temperature away from moisture and heat. Keep out of reach of children.
Do not use for more than 72 hours to avoid rebound redness.,Remove contact lenses before instillation; wait 15 minutes before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Report eye pain, vision changes, or persistent redness to your doctor.,Avoid use if you have glaucoma or are taking MAO inhibitors.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREFRIN-A vs VASOCON, answered by our medical review team.
PREFRIN-A is a Ophthalmic Decongestant/Antihistamine Combination that works by PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.. VASOCON is a Ophthalmic Decongestant that works by Vasoconstrictor; alpha-1 adrenergic receptor agonist causing smooth muscle contraction in blood vessels, reducing nasal congestion and ocular redness.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREFRIN-A and VASOCON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREFRIN-A is: 1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.. The standard adult dose of VASOCON is: Adults: 2 drops of 0.25% solution in each eye every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREFRIN-A and VASOCON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREFRIN-A is classified as Category C. Phenylephrine (sympathomimetic) and pyrilamine (antihistamine) combination. No adequate well-controlled studies in pregnant women. Phenylephrine may cause uterine vasoconstriction . VASOCON is classified as Category C. VASOCON (tetrahydrozoline) ophthalmic. Teratogenic risk: Category C. First trimester: No adequate human studies; animal studies not available. Second/third trimester: Potential mat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.